Literature DB >> 33499061

Detection and Characterization of Phosphorylation, Glycosylation, and Fatty Acid Bound to Fetuin A in Human Blood.

Markéta Kovářová1,2,3, Hubert Kalbacher4, Andreas Peter1,2,3, Hans-Ulrich Häring2,5, Triantafyllos Didangelos6, Norbert Stefan2,3,5, Andreas Birkenfeld2,3,5, Erwin Schleicher1,2,3, Konstantinos Kantartzis2,3,5.   

Abstract

The hepatokine fetuin A (Fet A) has been associated with diverse pathological states such as insulin resistance, type 2 diabetes, macrovascular disease, and systemic ectopic and vascular calcification. Fet A may also play a role in tumor growth and metastasis. The biological activity of Fet A may be affected by various modifications, including phosphorylation, O- and N-glycosylation and fatty acid binding. We developed an antibody-based assay for the detection of Fet A phosphorylated at serine 312. Fatty acid pattern was determined by gas chromatography. Using the antibody, we found that the phosphorylation was stable in human plasma or serum at room temperature for 8 h. We observed that Fet A is present in several glycosylation forms in human plasma, but the extent of Ser312 phosphorylation was not associated with glycosylation. The phosphorylation pattern did not change during an oral glucose tolerance test (0-120 min). We further found that human Fet A binds preferentially saturated fatty acids (>90%) at the expense of mono- and poly-unsaturated fatty acids. Our results indicate that different molecular species of Fet A are present in human plasma and that these different modifications may determine the different biological effects of Fet A.

Entities:  

Keywords:  FAM20C; fatty acid bound to fetuin A; fatty liver; fetuin A; glycosylation; obesity; phosphorylation

Year:  2021        PMID: 33499061      PMCID: PMC7865524          DOI: 10.3390/jcm10030411

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  45 in total

1.  Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor.

Authors:  S T Mathews; N Chellam; P R Srinivas; V J Cintron; M A Leon; A S Goustin; G Grunberger
Journal:  Mol Cell Endocrinol       Date:  2000-06       Impact factor: 4.102

2.  Plasma fetuin-A triggers inflammatory changes in macrophages and adipocytes by acting as an adaptor protein between NEFA and TLR-4.

Authors:  Satinath Mukhopadhyay; Samir Bhattacharya
Journal:  Diabetologia       Date:  2016-01-18       Impact factor: 10.122

3.  Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity.

Authors:  P Auberger; L Falquerho; J O Contreres; G Pages; G Le Cam; B Rossi; A Le Cam
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

Review 4.  Emerging Human Fetuin A Assays for Biomedical Diagnostics.

Authors:  Sandeep Kumar Vashist; E Marion Schneider; A G Venkatesh; John H T Luong
Journal:  Trends Biotechnol       Date:  2017-01-13       Impact factor: 19.536

5.  Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.

Authors:  Norbert Stefan; Anita M Hennige; Harald Staiger; Jürgen Machann; Fritz Schick; Stefan M Kröber; Fausto Machicao; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Diabetes Care       Date:  2006-04       Impact factor: 19.112

6.  Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer.

Authors:  László Kalabay; Lajos Jakab; Zoltán Prohászka; George Füst; Zsuzsa Benkö; László Telegdy; Zsolt Lörincz; Péter Závodszky; Philippe Arnaud; Béla Fekete
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-04       Impact factor: 2.566

7.  Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene.

Authors:  Suresh T Mathews; Gurmant P Singh; Mollie Ranalletta; Vivian J Cintron; Xiaoling Qiang; Anton Scott Goustin; Kai-Lin Catherine Jen; Maureen J Charron; Willi Jahnen-Dechent; George Grunberger
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

8.  Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A.

Authors:  Bernd Denecke; Steffen Gräber; Cora Schäfer; Alexander Heiss; Michael Wöltje; Willi Jahnen-Dechent
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

Review 9.  Noncardiovascular mortality in CKD: an epidemiological perspective.

Authors:  Dinanda J de Jager; Marc G Vervloet; Friedo W Dekker
Journal:  Nat Rev Nephrol       Date:  2014-02-04       Impact factor: 28.314

10.  PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans.

Authors:  Andreas Peter; Marketa Kovarova; Silvio Nadalin; Tomas Cermak; Alfred Königsrainer; Fausto Machicao; Norbert Stefan; Hans-Ulrich Häring; Erwin Schleicher
Journal:  Diabetologia       Date:  2014-06-29       Impact factor: 10.122

View more
  2 in total

Review 1.  Fam20C in Human Diseases: Emerging Biological Functions and Therapeutic Implications.

Authors:  Rongsheng Xu; Huidan Tan; Jiahui Zhang; Zhaoxin Yuan; Qiang Xie; Lan Zhang
Journal:  Front Mol Biosci       Date:  2021-12-20

2.  Chronic Diabetic Complications: Current Challenges and Opportunities.

Authors:  Ilias N Migdalis; Leszek Czupryniak; Nebojsa Lalic; Nikolaos Papanas; Paul Valensi
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.